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Objective: to evaluate the feasibility, acceptability, the ceiling and floor effects and the reliability 
of the Instrument to Measure the Impact of Coronary Disease on Patient’s Daily Life (IDCV) when 
applied to hypertensive patients. Method: one hundred and thirty seven hypertensive outpatients 
were interviewed, using questionnaires to collect sociodemographic and clinical data, followed by the 
IDCV. Reliability was assessed according to the temporal stability and internal consistency criteria. 
Results: the IDCV was applied in 8.0 (±3.0) minutes with 100% of the items answered. A ceiling 
effect of 31.4% was observed in the domain Adjustment to the Disease. The stability measure was 
observed for the total score and for all domains. There was evidence of internal consistency of the 
total IDCV (α=0.83) and the domains Physical Impact of the Disease – Symptoms (α=0.78) and 
Social and Emotional Impact of the Disease (α=0.74). Conclusion: the IDCV is an instrument of 
easy use and its reliability among hypertensive patients is evidenced. The domain Adjustment to 
the Disease, however, should be reviewed in further studies.
Descriptors: Nursing; Hypertension; Sickness Impact Profile.
Reliability and practical aspects of the disease impact measure
on hypertensive patients1
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Introduction
Systemic Arterial Hypertension (SAH) is currently 
considered one of the main chronic diseases in the world 
and one of the greatest public health challenges(1). In the 
last few years, SAH has been increasingly predominant 
and a major risk factor for cardiovascular diseases(1-2).
In a systematic review that included 44 studies 
in 35 countries, held from 2003 to 2008, a global 
predominance of SAH was shown in 37.8% of men and 
in 32.1% of women(3). In Brazil, in 2010, data collected 
from DATASUS pointed out that 23.3% of the population 
over the age of 18 reported previous medical diagnosis 
of hypertension (weighted percentage to adjust the 
socio demographic distribution of VIGITEL sample to 
the distribution of the adult population of Census 2000)
(4). A study involving the elderly population showed that 
34.9% of all reported diseases referred to self-reported 
hypertension(5).
The main purpose of treating SAH is to reduce the 
morbidity and mortality associated with high levels of 
blood pressure. The benefits of this treatment in relation 
to this reduction are effectively demonstrated. It is 
estimated that 40% of cerebrovascular accidents and 
about 25% of strokes in hypertensive patients can be 
prevented with appropriate anti-hypertensive therapy(3).
Despite the clinical benefits provided by the 
treatment, anti-hypertensive medications can have 
adverse effects, as well as the SAH itself, considering 
that the stigma of the diagnosis and the impact of its 
clinical expression may affect the pleasure of living(6). 
Therefore, one important aspect in the assessment and 
approach of hypertensive patients is the health related 
quality of life (HRQoL).
A baseline study carried out with hypertensive 
patients showed a reduced HRQoL among hypertensive 
patients when compared to the group without 
hypertension. When associating SAH with other 
comorbidities, an additional reduction of the HRQoL 
could be observed(7). These results indicate two 
important findings. The first relates to the importance 
of assessing the HRQoL of patients with cardiovascular 
diseases. The second is related to the relevance of 
providing a measure that is applicable to patients with 
cardiovascular diseases, with the purpose of measuring 
the same HRQoL construct and permitting intergroup 
comparison.
In the international literature, there are few specific 
instruments to assess the HRQoL of hypertensive 
patients, with emphasis on the Hypertension 
Health Status Inventory – HYPER 31(8), the Arterial 
Hypertension Quality of Life Questionnaire – Calidad de 
Vida en la Hipertensión Arterial - CHAL(9) and its reduced 
version of the Mini-Cuestionario de Calidad de Vida en 
la Hipertension Arterial – Minichal(10), which includes 
subjective aspects and somatic expressions, without 
restricting the evaluation of the effects of drug therapy 
on patients’ HRQoL.
Several generic and specific instruments have been 
validated for the assessment of HRQoL in patients with 
heart diseases(11-12), but studies aimed at measuring 
the perceived disease impact on the daily life of these 
people in a deeper way are rare.
In order to assess people’s perception regarding the 
impact of the disease on daily life, the IDCV – Instrument 
to Measure the Impact of Coronary Disease on Patient’s 
Daily Life – was developed, based on the Brazilian 
population, and is aimed at measuring the impact of 
coronary disease on patients(13). This instrument was 
shown to be valid and reliable when used in coronary 
disease patients being treated at outpatient clinics(14).
After validation studies of the IDCV(14), it was 
found that, due to the range of its items, it would also 
be possible to use the instrument in patients suffering 
from other cardiovascular diseases(15). Thus, the study 
which applied the IDCV in patients with coronary artery 
disease was conducted. Interestingly, the IDCV showed 
good psychometric performance, with evidences of 
internal consistency and construct validity(16), similar to 
the previous IDCV validation study involving coronary 
disease patients(14).
These findings suggested a new perspective on 
the use of the IDCV and aroused the interest in also 
investigating its measuring properties in relation to 
other groups of cardiovascular diseases, which share 
the symptoms and the chronic nature, such as the SAH.
This study investigated the acceptability, feasibility, 
ceiling and floor effects, as well as the reliability of the 
instrument to measure the Impact of Coronary Disease 
on Patient’s Daily Life when applied to hypertensive 
patients.
Method
Place of study
The study was developed at the hypertension 
outpatient clinic of a large university hospital and at 
the medical specialties outpatient clinic, both in the 
subspecialty of cardiology, located in two cities in the 
state of São Paulo.
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Subjects
One hundred and thirty seven hypertensive 
patients participated in this study, over the age of 18, 
male and female, under regular treatment at the above 
mentioned outpatient clinics, with medical diagnosis of 
hypertension reported in their medical records for at least 
one year. Patients with comorbidities that influenced the 
HRQoL were excluded (cancer, AIDS, chronic obstructive 
pulmonary disease, systolic heart failure functional class 
III and IV), as well as those with coronary diseases and 
with a history of ischemic coronary event in the last 
six months. Patients with a history of coronary artery 
disease, but who were submitted to medical follow ups at 
the time of the research only due to arterial hypertension, 
were included. Patients with verbal understanding and 
communication incapacity were excluded. The sample 
size was established by considering the coefficient of 
0.70, error margin of 0.10 and α=5% (n=137).
Data collection
Data collection was carried out from August 2011 
to January 2012, through individual interviews held in a 
private environment, in order to ensure the uniformity 
of information. The data were collected in two stages:
- First Stage (Tt): the data was initially collected 
by consulting the medical records of data related to 
socio demographic and clinical features and, then, the 
instrument IDCV was used.
- Second Stage (Trt): performed 7 to 21 days after the 
first stage (Tt). The IDCV was reapplied (retest) to 88 
participants who had responded to the IDCV (test) in the 
first stage of data collection.
Instrument
Instrument to Measure the Impact of Coronary Disease 
on Patient’s Daily Life - IDCV
This is a specific instrument used in studies to assess 
the perception of the disease impact. It is composed of 
two scales: the first (Part A), with 14 items, measures 
the perceptions related to the impact of the disease; 
the second scale (Part B), with 14 items, measures 
people’s assessment of each consequence of the disease 
mentioned in the first scale (whether it occurs or not 
in their lives). The answers to the items are presented 
in the Likert scale format, with answers that vary from 
(1) strongly disagree to (5) strongly agree for Part A. 
In Part B, the answers in the Likert scale vary from 
(1) very poor to (5) very good. The items are grouped 
in four domains: (a) Physical Impact of the Disease – 
Symptoms (items 11, 12 and 13); (b) Impact of the 
Disease on Daily Activities (items 5, 7, 9, 10 and 14); 
(c) Social and Emotional Impact of the Disease (items 2, 
3, 4 and 6) and (d) Adjustment to the Disease (items 1 
and 8). For each item assessed, the score is determined 
by the product of the scores obtained from Part A and 
Part B, which can generate a minimum score of 1 and 
a maximum score of 25. For the final calculation of the 
scores, items 1, 5 and 8 of Part A are inverted, since 
they reflect perceptions on the favorable impact of the 
disease. In Part B, the scores of all items are inverted 
and, the higher the score, the worse the assessment of 
patients about the statement(14). The higher the score, 
the higher the negative impact perceived by people 
and, on the contrary, the lower the score, the lower the 
perceived negative impact of the disease(14).
The total score of the IDCV is estimated based on 
the sum of all products obtained, and varies from 14 
to 350.
Data analysis
The data collected were entered into an electronic 
spreadsheet Software Excel for Windows 2010 through 
double entry, in order to ensure the quality and 
consistency of the data, and transferred to the program 
SAS – System for Windows (Statistical Analysis System), 
version 9.2. 2002 – 2008, for the analyses:
- Descriptive: Design of frequency tables, position and 
dispersion measures for the characterization of socio 
demographic and clinical data.
- Feasibility, acceptability and ceiling and floor effect: 
The feasibility of the IDCV was assessed through the 
time spent to complete the instrument. The practical 
aspects of the measure/acceptability were assessed by 
the percentage of unanswered items and the proportion 
of patients who had not answered all items(17). For the 
floor effect analysis, the percentage of patients who 
scored floor was calculated, that is, those who showed 
the worst 10% results in the IDCV, which are the 10% 
highest scores (which indicate higher negative impact 
of the disease)(17), for both the total IDCV (≥316.4) 
and for its domains (Physical Impact of the Disease – 
Symptoms ≥67.8, Impact of the Disease on the Daily 
Activities ≥113.0, Social and Emotional Impact of the 
Disease ≥90.4 and Adjustment to the Disease ≥45.2). 
The percentage of patients who scored ceiling(17) 
was also estimated, that is, those who showed the 
10% best possible results in the scale (thus, the 
lowest scores, which mean a lower negative impact: 
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total score ≤47.6, Physical Impact of the Disease 
– Symptoms ≤10.2, Impact of the Disease on daily 
Activities ≤17.0, Social and Emotional Impact of the 
Disease ≤13.6 and Adjustment to the Disease ≤6.8). 
Up to 25%, it was considered moderate ceiling and 
floor effect and, higher than 25%, it was considered 
substantial(18).
- Reliability: The reliability was assessed by estimating 
the measurement error, according to the temporal 
stability of the measure criterion, which is the consistency 
among repeated measures (test/retest) by means of 
the intraclass correlation coefficient and by internal 
consistency (Cronbach alpha coefficient)(16). A Cronbach 
alpha coefficient >0.70(19) was considered as evidence 
of internal consistency, and a coefficient >0.70(20-21) of 
temporal stability.
Ethical aspects
This study received approval from the local Research 
Ethics Committee (Registration number 1116/2010), 
and all patients listed signed an Informed Consent Term.
Results
Socio demographic and clinical data
The socio demographic and clinical characteristics 
of the 137 participants are presented in Table 1. The 
sample (n=137) consisted mostly of women (54.0%), 
with average age of 59.0 (±10.7), Caucasian (70.8%), 
married (67.2%), professionally inactive (65.0%). 
The average education in years was 6.1 (±4.3) and 
individual and family income of 1.5 (±1.4) and 2.7 
(±2.2) minimum salaries (MS) per month, respectively.
The studied group was characterized by the average 
time of 13.5 (±9.5) years of history of SAH; in relation to 
the associated clinical conditions, the most predominant 
was dyslipidemia (62.8%), followed by past or current 
smoking (48.2%) and diabetes mellitus (37.2%).
The average Body Mass Index was 29.7 (±5.2). All 
participants were using some type of antihypertensive 
medication, and 79.5% took Angiotensin Converting 
Enzyme Inhibitor (ACEI) or Angiotensin Receptor 
Blocker (ARB).
Table 1 - Socio Demographic and Clinical Characterization of Hypertensive Patients (n=137). Campinas, SP, Brazil, 2012
Socio demographic Variables N % Average (sd*) Median Variation
Age (in years) 59.8 (10.6) 60 21-87
Gender (female) 74 54
Race (Caucasian) 97 70.8
Education 6.1 (4.3) 5 0–21
Marital Status (with partner) 102 74.5
Employment Status
Inactive 93 67.8
Active 31 22.6
Housework 13 9.6
Monthly Individual Income (MS)† 1.5 (1.4) 1 0–7
Monthly Family Income (MS) 2.7 (2.2) 2 0–20
Clinical Variables
Time of SAH (in years) 13.5 (9.5) 11 1-50
Target Organs Damage
Coronary artery disease 24 17.5
Kidney failure 17 12.4
Heart failure 10 7.2
Cerebrovascular accident 3 2.1
Hypertensive Retinopathy 1 0.7
Associated Clinical Conditions
Dyslipidemia 86 62.8
Smoking 66 48.2
Diabetes Mellitus 51 37.2
Peripheral vascular disease 12 8.7
Body mass index 29.7 (5.2) 28.0 17.2-48.1
(continue...)
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Table 1 - (continuation)
Table 2 - Descriptive analysis of ceiling and floor effects of the Instrument to Measure the Impact of Coronary Disease 
on Patient’s Daily Life (IDCV) in hypertensive patients (n=137). Campinas, SP, Brazil, 2012
Table 3 – Intraclass correlation coefficient (ICC) and respective reliability intervals (IC95%) of the IDCV in patients 
with arterial hypertension (n=88). Campinas, SP, Brazil, 2012
*SD, standard deviation; †1 MS=R$ 510.00 in Dec/2010; 1 MS=R$ 540.00 from Jan/2011 to Dec/2011; 1 MS=R$ 622.00 in Jan/2012; ‡ACEI, angiotensin 
converting enzyme inhibitor; ARB, angiotensin receptor blocker
*Floor effect is equivalent to the 10% worst possible results in the scale; †Ceiling effect is equivalent to the 10% best possible results in the scale 
(Bennett, 2002)
*Intraclass correlation coefficient; † Reliability interval of 95%
Socio demographic Variables N % Average (sd*) Median Variation
Medications used per class
ACEI/ARB‡ 109 79.5
Diuretic 80 58.4
Alpha/Beta blocker 61 44.5
Calcium channel blocker 43 31.4
Vasodilators 3 2.2
Hypertension severity
Excellent 15 11
Normal 28 20.4
Borderline 29 21.2
SAH – Stage 1 44 32.1
SAH – Stages 2 and 3 18 13.1
Feasibility, Acceptability and Ceiling and Floor Effect 
and Descriptive Measures of the IDCV
The average time to complete the IDCV at Tt was 
8.0 (±3.0) minutes, ranging from 4.0 to 20.0 minutes. 
All patients answered 100% of the IDCV items, both 
at Tt and Trt, indicating high acceptability of the 
instrument. The descriptive measures of the IDCV, as 
well as the results of the assessment of the ceiling and 
floor effects, are shown in Table 2. The total IDCV score 
did not show a ceiling or floor effect. However, 31.4% 
of the participants scored “ceiling” in the Adjustment to 
the Disease domain.
Reliability of the IDCV
In order to assess reliability, the temporal stability 
and the internal consistency criteria presented in tables 
3 and 4, respectively, were considered.
To assess temporal stability, the IDCV was reapplied 
to 88 patients at Trt, with an interval of 7 to 21 days. 
Satisfactory consistency indexes between the results 
of the two stages of use were found, as shown by the 
intraclass correlation coefficients. There was evidence of 
satisfactory internal consistency for the instrument as a 
whole (Cronbach alpha=0.83), as well as for two of its 
four domains: Physical Impact of the Disease – Symptoms 
(Cronbach alpha=0.78) and Social and Emotional Impact 
of the Disease (Cronbach alpha=0.74).
    Domain Average (sd) Median Variation Floor Effect* Ceiling Effect
† Floor 
Effect %
Ceiling 
Effect %
Physical Impact of the Disease – Symptoms 38.5 (21.1) 49.0 12-75 Scores ≥67.8 Scores ≤10.2 12.4 -
Impact of the Disease on Daily Activities 58.1 (23.4) 64.0 18-110 Scores ≥113.0 Scores ≤17.0 - -
Social and Emotional Impact of the Disease 45.1 (24.0) 54.0 15-100 Scores ≥90.4 Scores ≤13.6 2.9 -
Adjustment to the Disease 13.3 (8.3) 9.0 2-40 Scores ≥45.2 Scores ≤6.8 - 31.3
Total – IDCV 155.0 (60.7) 172.0 54-298 Scores ≥316.4 Scores ≤47.6 - -
Variable ICC* ICC 95%†
Physical impact of the disease 0.998 [0.996-0.998]
Impact of the disease on daily activities 0.996 [0.994-0.997]
Social and emotional impact of the disease 0.996 [0.993-0.997]
Adjustment to the disease 0.994 [0.991-0.996]
Total IDCV 0.998 [0.998-0.999]
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Table 4 - Item-total correlation and Cronbach alpha coefficient of the Instrument to Measure the Impact of Coronary 
Disease on Patient’s Daily Life (IDCV) in hypertensive patients(n=137). Campinas, SP, Brazil, 2012
Variable
Total item 
score/
domains 
correlation
Item/total 
score 
correlation
Cronbach 
Alpha
Cronbach 
Alpha 
of the 
domain 
if item 
deleted
Cronbach 
Alpha of 
the total 
score 
if item 
deleted
Total IDCV 0.83
Physical Impact of the Disease – Symptoms 0.78
11 Due to the heart problem, I often have shortness of breath 0.62 0.62 0.70 0.81
12 Due to the heart problem, I feel very tired 0.64 0.57 0.68 0.81
13 Due to the heart problem. I often feel dizzy 0.60 0.56 0.73 0.81
Impact of the Disease on Daily Activities 0.57
5 I cope well with my heart problem 0.20 0.86 0.58 0.83
7 After I got the heart problem, I started to fear that
something could happen to me
0.44 0.44 0.44 0.82
9 Due to the heart problem, I have difficulty sleeping 0.25 0.46 0.56 0.82
10 Due to the heart problem, I have a lot of difficulty performing daily tasks 0.39 0.63 0.48 0.81
14 Having a heart problem concerns me 0.39 0.32 0.48 0.83
Social and Emotional Impact of the Disease 0.74
2 The heart problem made me become dependent on other people 0.43 0.41 0.74 0.82
3 My heart problem affected my ability to work like before 0.63 0.61 0.63 0.81
4 I now feel more irritated and stressed due to the heart problem 0.60 0.62 0.65 0.81
6 I feel very anxious after I got a heart problem 0.50 0.59 0.71 0.81
Adjustment to the Disease -0.01
1 After I got a heart problem, I started to pay more attention to my health - 0.11 - 0.83
8 My sexual life remained the same as before I got the heart problem 0.15 0.84
Discussion
This study was aimed at assessing the practical 
aspects of the measure in relation to the use of the 
IDCV in hypertensive patients, verifying its feasibility, 
acceptability, ceiling and floor effects and reliability. The 
findings showed that the use of the instrument in this 
group of patients is feasible.
The feasibility and acceptability are important 
aspects to be evaluated in relation to an instrument 
that is developed, adapted or tested in a population 
that is different from that it was originally developed for. 
The analysis of these properties permits verifying the 
instrument’s feasibility for the new target population.
The study findings evidence these properties, since 
there is a low onus to the respondent as a result of the 
eight-minute average time for its use, besides the fact 
that no unanswered items were registered. These data 
show the IDCV performance in patients with coronary 
artery disease(15). However, it should be emphasized 
that, in both studies, the instrument was applied in the 
form of an interview, which can reduce the chances of 
unanswered items.
The analysis of the ceiling and floor effects, based 
on the analysis of the distribution of scores (total and 
domains), showed that the IDCV is an instrument 
potentially capable of detecting improvement or 
worsening in the perception of HRQoL over time(20).
The ceiling effect is confirmed when there is 
asymmetric distribution of scores and a significant 
percentage of the population in the study scores at the 
highest levels of the measure. This means that, if the 
subject who scored at the extreme range of the scale 
presents an improvement in the perceived HRQoL, the 
instrument will not be able to detect it.
The IDCV as a whole showed no ceiling effect, 
nor did its domains, except for Adjustment to the 
Disease, which showed a moderate ceiling effect, 
similar to the study undertaken with coronary disease 
patients(15). This means that the IDCV, when applied 
to hypertensive patients, is potentially capable of 
detecting improvements in the perception of HRQoL 
over time.
The floor effect, in turn, reflects the percentage of 
subjects who score at the lowest levels of the measure. 
This type of asymmetric distribution makes it hard to 
detect the worsening in the assessed subjects’ perceived 
HRQoL(17). A slight floor effect (12.4%) was observed 
among hypertensive patients, only in relation to the 
domain Physical Impact of the Disease – Symptoms, and 
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this effect was even smaller than that verified among 
patients with coronary artery diseases (49.0%)(15).
The investigation of the ceiling and floor effects 
is important because, if observed in many domains, 
these effects can lead to the limitation of another 
psychometric property: responsiveness. This property, 
also important, is related to the instrument’s ability to 
detect and estimate the magnitude of change in the 
health status over time(20).
Whereas one of the methods for assessing 
responsiveness consists of an approach based on the 
longitudinal distribution of the sample, any reduction in 
the variability of the scores, that is, ceiling and floor 
effects can minimize the sensibility to detect differences 
and the responsiveness to change(21-22). 
Another property involved in the feasibility of the 
responsiveness assessment of an instrument is the 
demonstration of its temporal stability. Within a certain 
range, which is variable according to the studied 
concept, it is important that the subjects’ answers to 
the instrument do not vary substantially, since there 
is no greater modification factor that may affect their 
perception of the studied concept. This property is 
named temporal stability and was assessed in the range 
7 to 21 days in this study. High levels of consistency 
between the test/retest were observed, in relation to 
the total score as well as all domains of the IDCV.
Thus, the absence of the ceiling and floor effects 
for the total score and for most of the domains of 
the IDCV, as well as the strong evidence of temporal 
stability, confirm the development of subsequent studies 
to assess the responsiveness of the IDCV, in the light of 
clinical changes concerning hypertensive patients.
The IDCV also presented evidence of being 
composed of homogeneous and correlated items, that is, 
of internal consistency, which was shown by the values 
of the Cronbach alpha coefficient for the IDCV as a whole 
(α=0.83) and for two of its domains: Physical Impact 
of the Disease – Symptoms (α=0.78) and Social and 
Emotional Impact of the Disease (α=0.74). The Impact 
of the Disease on the Daily Activities domain presented 
alpha coefficient lower than 0.70 but higher than 0.50, 
which also allows the interpretation of its data. This 
was not observed for the Adjustment to the Disease 
domain which, as shown by other previous studies with 
the use of the IDCV(14-15), presented low homogeneity. 
This is a domain constituted by only two items, which 
reduces the variability of its score. In addition, the 
development characteristic of these two items can cause 
double interpretation and, as a result, inconsistency in 
the scores given by the patient to answer the question. 
Item 1 (After I got a heart problem, I started to pay more 
attention to my health) can be interpreted ambiguously 
as a good or bad outcome. In turn, item 8 (My sexual life 
remained the same as before I got the heart problem), 
may hinder the assessment of the outcome, since it 
does not show any mention to sexual life before the 
development of the disease.
Besides low internal consistency, the items of this 
domain presented a very low correlation with the total 
score of the instrument, and it was the only one to show 
a ceiling effect.
The study findings show similar findings 
concerning the feasibility of the IDCV in other groups 
presenting cardiovascular diseases, which reiterates the 
recommendation to review or exclude the items that 
compose this domain.
Conclusion
The use of the IDCV in hypertensive patients 
showed to be feasible, acceptable and potentially 
sensitive to detect worsening or improvement in the 
perceived disease impact evidenced by the absence of 
ceiling and floor effect in the total score of the IDCV and 
in most of its domains. The findings indicate that the 
instrument is reliable in relation to temporal stability 
and internal consistency. The validity properties of the 
IDCV in hypertensive patients will be disclosed in a 
subsequent article.
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